Latest filing published 19 Dec 2022 for Inozyme Pharma, Inc., €28k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Henric Bjorn Bjarke: trading record in brief
Henric Bjorn Bjarke, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Inozyme Pharma, Inc. and IVERIC bio, Inc. The record holds 5 filings, for trades running from 4 January 2017 to 15 December 2022.
Both buying and selling appear: 2 purchases worth €121k, against 1 sale worth €1,493. Taken together, the purchases exceed the sales by €119k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 1 share grant and 1 option exercise. So far in 2022, the count stands at 2 purchases and no sales.
On 19 December 2022 came the latest disclosure, an open-market purchase for €28k in Inozyme Pharma, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Henric Bjorn Bjarke
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 21,500 shares@ US$1.3921.8% of flowCommon StockSEC:0001209191-22-061766:0Canonical exit: 15 Mar 2023 (T+90)
- 3,315 shares@ US$2.286.0% of flowCommon StockSEC:0001209191-22-052022:0
- 27,100 shares@ US$3.6972.2% of flowCommon StockSEC:0001209191-22-024918:0Canonical exit: 18 Jul 2022 (T+90)
3 of 3 declarations
